...
首页> 外文期刊>European journal of cardio-thoracic surgery: Official journal of the European Association for Cardio-thoracic Surgery >Oral sildenafil for persistent pulmonary hypertension early after congenital cardiac surgery in children.
【24h】

Oral sildenafil for persistent pulmonary hypertension early after congenital cardiac surgery in children.

机译:儿童先天性心脏手术后早期口服西地那非治疗持续性肺动脉高压。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: Sildenafil is a strong pulmonary vasodilator that increases the intracellular cyclic guanosine monophosphate concentration through inhibition of phosphodiesterase-5. We assessed the benefit of oral sildenafil for persistent pulmonary hypertension early after congenital cardiac surgery in paediatric patients. METHODS: Sildenafil was administered at a starting dose of 0.5 mg kg(-1) following admission to the intensive care unit. With careful monitoring of haemodynamics, the dose was increased stepwise by 0.5 mg kg(-1) every 4-6 h up to a maximum of 2 mg kg(-1). After successful weaning from a ventilator and from other vasodilators, sildenafil was gradually discontinued over the next 5-7 days. RESULTS: A retrospective review of medical records showed an age distribution of <1 month (n=26), > or = 1-<6 months (n=36), > or = 6-<12 months (n=19), 1-3 years (n=8), 4-9 years (n=9) and >10 years (n=2) at the time of surgery. The surgeries were performed for ventricular septal defect closure (n=17), arterial switch (n=30), truncus arteriosus repair (n=10), complete atrioventricular septal defect repair (n=12), total anomalous venous drainage repair (n=9), and other open-heart surgery (n=22). The aforementioned concomitant inhaled nitrous oxide treatment was performed in 66 patients. Pulmonary arterial pressure decreased in 28, was unchanged in five and elevated in one patient out of the total of 34 cases for which data from continuous pressure monitoring were available. Bosentan was added in three cases with persistent symptoms due to pulmonary hypertension despite sildenafil treatment. After sildenafil administration, modest oxygen desaturation occurred in seven cases, but no 'rebound' pulmonary hypertension occurred. There were no significant adverse events during sildenafil treatment. CONCLUSIONS: Our results suggest that oral sildenafil is a safe and effective alternate for persistent pulmonary hypertension following congenital heart surgery in children.
机译:目的:西地那非是一种强大的肺血管扩张剂,可通过抑制磷酸二酯酶-5来增加细胞内环鸟苷单磷酸的浓度。我们评估了先天性心脏手术后小儿患者口服西地那非对持续性肺动脉高压的益处。方法:重症监护病房入院后,西地那非的起始剂量为0.5 mg kg(-1)。在仔细监测血流动力学的情况下,剂量每4-6小时逐步增加0.5 mg kg(-1),最大增加到2 mg kg(-1)。从呼吸机和其他血管扩张剂成功断奶后,西地那非在接下来的5-7天逐渐停用。结果:回顾性医疗记录显示年龄分布为<1个月(n = 26),>或= 1- <6个月(n = 36),>或= 6- <12个月(n = 19),手术时为1-3年(n = 8),4-9年(n = 9)和> 10年(n = 2)。进行了以下手术:室间隔缺损闭合(n = 17),动脉开关(n = 30),截肢动脉修复(n = 10),完全房室间隔缺损修复(n = 12),总异常静脉引流修复(n = 9),以及其他开胸手术(n = 22)。 66例患者接受了上述同时吸入一氧化二氮治疗。在可获得连续压力监测数据的34例患者中,有28例肺动脉压降低,5例未变,1例升高。尽管接受西地那非治疗,但三例因肺动脉高压而持续出现症状的患者中加入波生坦。西地那非给药后,有7例发生了适度的氧饱和度降低,但未发生“反弹”肺动脉高压。西地那非治疗期间无明显不良反应。结论:我们的结果表明,口服西地那非是儿童先天性心脏手术后持续存在的肺动脉高压的安全有效替代方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号